ASP0113
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Allogeneic Hematopoietic Cell Transplant
Conditions
Allogeneic Hematopoietic Cell Transplant
Trial Timeline
Jun 20, 2013 → Jan 19, 2015
NCT ID
NCT01903928About ASP0113
ASP0113 is a phase 2 stage product being developed by Astellas Pharma for Allogeneic Hematopoietic Cell Transplant. The current trial status is completed. This product is registered under clinical trial identifier NCT01903928. Target conditions include Allogeneic Hematopoietic Cell Transplant.
What happened to similar drugs?
0 of 2 similar drugs in Allogeneic Hematopoietic Cell Transplant were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01903928 | Phase 2 | Completed |
Competing Products
9 competing products in Allogeneic Hematopoietic Cell Transplant
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Valganciclovir + Ganciclovir | Roche | Phase 3 | 32 |
| Blinatumomab in combination with donor lymphocyte infusion | Amgen | Phase 2 | 27 |
| Denosumab | Amgen | Phase 2 | 35 |
| DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa + heptavalent pneumococcal conjugate vaccine, Prevenar | Pfizer | Phase 3 | 40 |
| Inotuzumab Ozogamicin + Vincristine Sulfate Liposome | Pfizer | Phase 1/2 | 24 |
| Genotropin (Recombinant Human Growth Hormone) | Pfizer | Phase 1 | 21 |
| immunosuppression | Pfizer | Phase 2 | 27 |
| Mycophenolate Mofetil | Hikma Pharmaceuticals | Pre-clinical | 20 |
| Vancomycin Pre-Treatment + Vancomycin Placebo + SER-155 + SER-155 Placebo | Seres Therapeutics | Phase 1 | 19 |